TSO3 Inc

TSO3 — Investor Presentation (May 2016)

26 slides from TSO3's investor presentation, May 2016

  1. Slide 1: Creating the Improved Standard in Healthcare Sterile Reprocessing

    TSX:TOS Creating the Improved Standard in Healthcare Sterile Reprocessing™ Corporate Presentation May 2016

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts (including, without limitation, those regarding the timing

  3. Slide 3: TSO3 - Our Vision

    TSO3 - Our Vision TSX:TOS To Create the Improved Standard in Healthcare Sterile Reprocessing™ 3

  4. Slide 4: Where We Are From and Where We Are Going

    Where We Are From and Where We Are Going TSX:TOS 2009 - 2014 2016 • Reworked products • Record revenue and • Introduced STERIZONE® assembly capacity growth 125L+ and STERIZONE® VP4 • 91M shares oustanding1 Sterilizers • US$24.4M in cash2 • 18 sterilizers in operation at Canadian hospitals 2001 IPO •

  5. Slide 5: Large Target Market

    Large Target Market TSX:TOS Global Sterilization Equipment Market1  Global sterilization equipment market is expected to grow ($ billions) at a 7.6% CAGR to $6.1 billion by 20201 Impossible d’afficher l’image. $6.1B  Consumables and accessories are in excess of equipment $5.7B and are projected to

  6. Slide 6: TSO3 Offers Better Care

    TSO3 Offers Better Care Impossible d’afficher l’image. TSX:TOS  Break the cycle of infection  Provides a sterile instrument every time  Instruments are ready when required  Single Cycle = Error free process, the right instrument, the right cycle 6

  7. Slide 7: STERIZONE VP4 Sterilizer

    STERIZONE® VP4 Sterilizer TSX:TOS FDA-Cleared - Dual Sterilant, Low Temperature Sterilization System - Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, fewer Proprietary Software automatically operator errors due to error free adjusts the sterilant quantity based on cycle

  8. Slide 8: Lower Cost

    Lower Cost TSX:TOS  Superior capacity utilization  Superior inventory utilization  Superior user interface  Superior economics for hospital 8

  9. Slide 9: Innovative Patented Approach

    Innovative TSX:TOS Patented Approach Three Key Differentiators 1 - ONLY dual chemistry sterilizer ever cleared by the FDA 2 - ONLY Variable dose sterilizer, we dose based on load content 3 - ONLY “wet” process assuring sterilant in, on and around medical devices 9

  10. Slide 10: Sterilizing Agents

    Sterilizing Agents TSX:TOS H2O2 Small Quantity of O3 (Ozone) Hydroxyl Radical Event 10

  11. Slide 11: All loads are not created equal, so should not be treated the same

    TSX:TOS All loads are not created equal, so should not be treated the same Bigger load, more chemistry required… 11

  12. Slide 12: The Science

    The Science + Se. ) TSX:TOS 30 25 Concentration of 125-280 Solution™ (50 wt%) rs) 5 Liquid & iq 245 a 3 Convergence of 2 19 theoretical and Theoretical dew 5 empirical values point pressure € (condensation & begins) ) 0 0.2 0.2 0.3 0.4 0.5 0.6 07 0.8 0.9 1 Molar fraction —~ Measured H202 vapor conce

  13. Slide 13: The Impact

    The Impact TSX:TOS STERIZONE® VP4 Ability to Provide Sterile Sterilizer Devices to All Patients 13

  14. Slide 14: Process Innovation

    Process Innovation TSX:TOS  “A better Mouse Trap” than incumbent low- temperature sterilization solutions  More instruments in same cycle  Different instruments in same cycle  Enables an entirely new healthcare practice  Can also replace high level disinfection 14

  15. Slide 15: Increasing the Need for Low-Temperature Sterilization

    MIS Device and Endoscope Use - Increasing the Need for Low-Temperature Sterilization TSX:TOS  30 million+ Minimally Invasive Surgery (MIS) operations annually in U.S. and growing  Expensive, complex and delicate equipment requires low temperature processes  Many MIS devices and endoscopes (such a

  16. Slide 16: The Superbug Problem

    The Superbug Problem TSX:TOS  SUPERBUG = Antimicrobial Resistant Bacteria  2 million+ Americans suffer from antibiotic-resistant bacteria annually – 23,000 die1  Half of all bugs that cause infections after surgery are antibiotic resistant2  CRE superbug has become resistant to most available an

  17. Slide 17: Exclusive Global Distribution Agreement

    TSO3 and Getinge Infection Control Exclusive Global Distribution Agreement TSX:TOS “The STERIZONE® VP4 Sterilizer uniquely  Getinge - exclusive global distributor rights to addresses an unmet global need for cost STERIZONE® VP4 Sterilizer - Q4 2015 effective, high throughput sterilization of comple

  18. Slide 18: Growth Strategies

    Growth Strategies TSX:TOS  Support Getinge for global introduction and Medical Reprocessing Lifecycle commercialization of STERIZONE® VP4 Sterilizer  Expand manufacturing/assembly operations  Broaden product portfolio:  Sterilizer products purpose-built for the operating room (OR)  Iterations o

  19. Slide 19: TSO3 Key Takeaways

    TSO3 Key Takeaways TSX:TOS  STERIZONE® VP4 Sterilizer: FDA-cleared medical device sterilization system with multiple Global Distribution Partner breakthroughs in design, capability, effectiveness and operational cost  Exclusive, performance-based global distribution agreement with Getinge: minimum

  20. Slide 20: Q1 2016 Financial Highlights – USD

    Q1 2016 Financial Highlights – USD TSX:TOS Quarterly Revenue  Revenues totaled a record $3.1M, primarily driven (US$ Millions) by 25 STERIZONE ® VP4 Sterilizers shipped to Getinge Shipped 25 STERIZONE® VP4 $3.1M Sterilizers to Getinge in the U.S.  Gross profit increased to $1.1M or 36% of revenues

  21. Slide 21: Key Stats (TSX: TOS)

    Key Stats (TSX: TOS) All Dollars in USD TSX:TOS Stock Price (5/17/16) $ 1.66 Total Revenue (ttm) $4.3M Distributor (Getinge) 5-Year Sales Target 52 Week High-Low $1.04-$1.88 Gross Profit (ttm) $0.9M Avg. Daily Vol. (3 mo.) 0.2M High-margin consumables and Net Loss (ttm) $(4.2)M maintenance offer sub

  22. Slide 22: Contact Us

    Contact Us TSX:TOS Investor Relations TSO3 Inc. - Canada Liolios Group, Inc. 2505, avenue Dalton Ron Both, Senior Managing Director Tel (949) 574-3860 Québec, Québec TOS@liolios.com G1P 3S5 CANADA Renmark Financial Communications Inc. Tel (418) 651-0003 Barry Mire, Vice President info@tso3.com Tel (

  23. Slide 23: Appendix

    Appendix +,

  24. Slide 24: Evolution of TSO3 – From Development Stage to Major Commercial Rollout

    Evolution of TSO3 – From Development Stage to Major Commercial Rollout TSX:TOS 2000 2009 2010 2015 2015 2015 2015 125L Ozone Sterilizer Health Canada Received CE Mark Completed Additional Established Allowed received regulatory licenses notice of conformity CAD$11.5 million patent first U.S. expande

  25. Slide 25: Important Regulatory Growth Driver

    Important Regulatory Growth Driver TSX:TOS  FDA identified flexible endoscopes as known source of infection and cause of death  FDA has recorded 109 reports of infections or FDA safety communication: contamination related to bronchoscopes over the Design of endoscopic retrograde cholangio- pancrea

  26. Slide 26: Evolution of Classification of Reprocessing Requirements

    Potential Future Regulatory Growth Driver: Evolution of Classification of Reprocessing Requirements TSX:TOS  Since multi-channeled flexible Body Reprocessing FDA Device Class endoscopes, including Highest Contact Requirements Today Signaled colonoscopes and duodenoscopes are typically Sterile Body

TSO3 — Investor Presentation (May 2016) on 6ix